Efficacy and Safety of 5 Alpha-Reductase Inhibitor Monotherapy in Patients with Benign Prostatic Hyperplasia: A Meta-Analysis
October 2018
in “
PLOS ONE
”
Studysummary This study found that 5-alpha-reductase inhibitor monotherapy for symptomatic benign prostatic hyperplasia showed some clinical benefit over placebo but was linked to a higher incidence of sexual side effects.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on journals.plos.org →